Moderna’s mRNA Flu Shot Faces FDA Scrutiny

Moderna’s new mRNA flu vaccine, mFlusiva, is poised to revolutionize flu protection for seniors—fast, flexible, and potentially more effective than ever before. Designed to keep pace with flu’s ever-changing mutations, it’s already showing strong antibody responses in early trials, even outperforming traditional high-dose shots in some cases. The FDA is reviewing its request for full approval for ages 50–64, with authorization for 65+ still pending more data. A recent FDA official’s initial hesitation over study comparisons has been countered by Moderna, citing prior FDA approval of the trial design and promising results. But caution remains: critical gaps in data for the most vulnerable—frail elderly and immunocompromised individuals—still need addressing. This isn’t just about a new shot; it’s about smarter, faster, and safer flu defense for the people who need it most. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3a134b55b3b68a42